Cipla (LUX:CIPLA) Total Equity: $3,719 Mil (As of Mar. 2026)


LUX:CIPLA Cipla Ltd LUX:CIPLA
94 GF Score
Price $18.10
GF Value $19.69
! 5 Warning Signs
View Full Analysis

What is Cipla Total Equity?

Cipla LUX:CIPLA 94 Total Equity is $3,719 Mil as of Mar. 2026. GuruFocus rates LUX:CIPLA with a GF Score™ of 94/100 and a GF Value™ of $19.69. The stock has 5 warning signs investors should review.

Cipla's total equity for the quarter that ended in Mar. 2026 was $3,719 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Cipla Total Equity Historical Data

* Premium members only.

The historical data trend for Cipla's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Total Equity Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,771.69 2,882.53 3,228.36 3,616.36 3,719.12

Cipla Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,616.36 0.00 3,739.17 0.00 3,719.12
LUX:CIPLA
94GF Score
Cipla Ltd LUX:CIPLA
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cipla Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Cipla's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=4578.41-859.286
=3,719

Cipla's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=4578.41-859.286
=3,719

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $3,719 Mil mean?
Cipla (LUX:CIPLA) has a Total Equity of $3,719 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Cipla and its competitors.
Is Cipla's Total Equity too high?
Cipla's current Total Equity is $3,719 Mil. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's Total Equity compare to ZTS and UTHR?
Cipla's Total Equity of $3,719 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Cipla and its competitors. Cipla's current Total Equity is $3,719 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current Total Equity of $3,719 Mil. The stock's GF Value™ is $19.69, compared to a current price of $18.10 — trading 8.1% below its estimated fair value. The current Total Equity is $3,719 Mil. Cipla's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current Total Equity is $3,719 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cipla (LUX:CIPLA) Overvalued in 2026?

Based on GuruFocus' analysis, Cipla stock appears to be undervalued. The current stock price of $18.10 is trading 8.1% below its estimated GF Value™ of $19.69.

Key valuation signals for LUX:CIPLA:

  • Total Equity: $3,719 Mil
  • GF Value™: $19.69 vs. price of $18.10 (8.1% below fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
94GF Score

Get the complete analysis for LUX:CIPLA

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$18.10
Price
$19.69
GF Value